Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Theralase Techs Inc (TLTFF)

Theralase Techs Inc (TLTFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1893 +2.85%
on 02/19/26
0.2409 -19.18%
on 02/12/26
-0.0303 (-13.47%)
since 02/09/26
3-Month
0.1052 +85.08%
on 12/15/25
0.2594 -24.94%
on 01/12/26
+0.0840 (+75.88%)
since 12/09/25
52-Week
0.1019 +91.07%
on 11/25/25
0.2594 -24.94%
on 01/12/26
+0.0138 (+7.63%)
since 03/07/25

Most Recent Stories

More News
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with InterferonToronto, Ontario--(Newsfile Corp. - March 2, 2026) - Theralase®...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.Toronto, Ontario--(Newsfile Corp. - February 20, 2026) - Theralase® Technologies...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase(R) Provides Update on Bladder Cancer Clinical Study

Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete responseToronto, Ontario--(Newsfile Corp. - February...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering...

TLT.VN : 0.265 (-1.85%)
TLTFF : 0.1947 (-1.32%)

Key Turning Points

3rd Resistance Point 0.2063
2nd Resistance Point 0.2035
1st Resistance Point 0.2004
Last Price 0.1947
1st Support Level 0.1945
2nd Support Level 0.1917
3rd Support Level 0.1886

See More

52-Week High 0.2594
Fibonacci 61.8% 0.1992
Last Price 0.1947
Fibonacci 50% 0.1806
Fibonacci 38.2% 0.1621
52-Week Low 0.1019

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar